The present investigation, focused on screening of various fungal species for Lovastatin production using different agro-based wastes, also, for maximizing lovastatin productivity by isolated Aspergillus fumigatus using response surface methodology (RSM). The following substrates (Olive cake; Pea pods; sugarcane bagasse; wheat bran; rice hulls; beet peel; Potato peel and groundnut shells) were screened to evaluate their effectiveness for lovastatin production, using different fungal species, (Aspergillus niger; Rhizopus oligosporus; Penicillium citrinum and isolated Aspergillus fumigatus) under solid state fermentation (SSF). Wheat bran was the most suitable substrate for lovastatin production with all fungal species. Optimum conditions of lovastatin production by wheat bran have been attained efficiently by response surface methodology (RSM) using isolated Aspergillus fumigatus under solid state fermentation (SSF). The lovastatin yield of (3.353 mg/g DFM) was obtained at an optimum temperature of 28 °C; pH of 5.00; initial moisture content of 70% and incubation period of 12 days. This Lovastatin has the possibility to use in different therapeutic applications.

Exopolysaccharide (LB-gum) was produced from Lactobacillus helveticus by ethanol precipitation and gel-permeation chromatography. The structures of LB1 and LB2 were estimated by sugar composition analysis, methylation, and FT-IR analysis. The results proved the contents of glucose and galactose in molar ratio of 2:1 and 2.3:1, and molecular weights ∼5.4 × 10 5 Da and ∼20.3 × 10 5 Da, respectively. Xanthan and LB-gum were added to wheat flour during biscuits making at levels of 0, 0.5, 1.0, 1.5, and 2.0%. Rheological properties and chemical quality attributes of the biscuits during storage for six months were evaluated. The data revealed slight increases in water absorption, dough development time, and dough stability but weakening decreased about 50 %. Also, height, weight, volume, and specific volume were found to increase as xanthan and LB-gum level increased. The colour was slightly affected. There were no significant differences between the samples containing xanthan and LB-gum at different levels with respect to all parameters tested except for the taste. Shelf -life of biscuit prolonged as a result of xanthan or LB-gum addition. The best addition level to improve the biscuits quality was 1.0% of xanthan or 1.5% of LB-gum.

This research aimed to examine the antioxidant polysaccharide activity (PsPc-3) derived from Pleurotus columbinus (P. columbinus) on oxidative renal injury (ORI) induced by cisplatin (CP). The principal components of crude polysaccharide were assessed. We studied the preventive impact of polysaccharide on cisplatin-induced renal damage in this study. For 21 days, we employed the CP-induced ORI rat model and divided the rats into four groups: control, CP alone, polysaccharide post CP (100 mg/kg) orally, and CP + polysaccharide (pre and post). The chemical characterization of the polysaccharide fraction PsPc-3 stated that protein was not present. PsPc-3 contained 7.2% uronic acid as assessed as 0% sulfate. PsPc-3 hydrolysate structured of Galacturonic:Glucose:Xylose and their molar proportions were 1:4:5, respectively. The average molecular weight (Mw) and molecular mass (Mn) per molecule of PsPc-3 were 5.49 × 104 g/mol and Mn of 4.95 × 104 g/mol respectively. DPPH radical scavenging activity was demonstrated by the polysaccharide of 65.21–95.51% at 10 mg/ml with IC50 less than 10 mg/ml. CP increased serum urea to 92.0 mg/dl and creatinine up to 1.0 mg/dl, with a concurrent decrease in the levels of total protein to 4.0 mg/dl. Besides, Also, CP-induced ORI raised levels of malondialdehyde (MDA), alkaline phosphatase (ALP), and renal hormones (renin and aldosterone), with a decline in antioxidants compared to control rats. In addition, in the presence of CP, interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-alpha) levels increased. PsPc-3 decreased these changes dramatically. PsPc-3 improves pathological renal damage caused by CP and decreases tubular apoptosis measured by DNA ladder formation and cleaved caspase- 3. These findings showed that PsPc-3 isolated from P. columbinus protects and inhibits tubular apoptosis in cisplatin-induced ORI. Furthermore, PsPc-3 has no influence on the anticancer efficacy of CP in rats. Thus, PsPc-3 derived from P. columbinus might provide a novel therapy method for cisplatin-induced nephrotoxicity.

The exopolysaccharide (EPS) was produced by a halophilic bacterial strain isolated from marine sediments, Porto-Elsokhna Beach, Egypt. This isolate has been defined morphologically and physiologically and has been recognized by 16S rDNA as Bacillus axarquiensis NRC G6.This strain was deposited in the Gene Bank (http://www.ncbi.nlm.nih. gov) under the accession number of KU945823. The EPS produced was fractionated by precipitation and listed the primary fraction as EPSBa3. Through FT-IR and HPLC, further work attempted to elucidate the structural function of EPSBa3. The findings showed that EPSBa3 was an acidic EPS composed of glucuronic: mannose: galacturonic: glucose and xylose, respectively, in a molar ratio of 1:1:3:3:3. The proportion of uronic acid and sulfate was 13.9% and 7% respectively. The estimated median molecular weight (Mw) and molecular number (Mn) were 1.499 X10 6 and 1.29 X 10 6 g / mol. In rats, the antiinflammatory activity of exopolysaccharide (EPSBa3) was also explored using paw edema induced by carrageenan. EPSBa3 caused important anti-inflammatory effects on the carrageenan model by 50 mg/kg orally. In catalase (CAT) and superoxide dismutase (SOD) enzymes and GSH content, the EPSBa3 enhanced declines. In addition, the content of nitric oxide (NO), lipid peroxidation (LPO) and reactive oxygen species (ROS) arising from carrageenan-induced edema were considerably reduced following therapy with EPSBa3. In addition, the findings showed that interleukin-6 (IL-6) protein expression was decreased after EPSBa3 treatment leading to alleviate paw edema. These findings stated that to avoid inflammatory diseases, EPSBa3 could be utilized as a source of natural products .